Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch

Xu, Qingyong; House, Andrew A.; Leckie, Steve; Gunaratnam, Lakshman; Luke, Patrick; Jevnikar, Anthony M.

doi:10.1016/j.humimm.2019.03.015

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Si bien la FCXM es un método con excelente sensibilidad y especificidad, también comparte varios de los problemas asociados a las pruebas celulares (24,37,38). Entre los problemas más importantes, podemos mencionar la unión inespecífica de las inmunoglobulinas a los FcR, los autoanticuerpos no HLA y el uso de anticuerpos terapéuticos para inducción de la inmunosupresión, como rituximab (anti-CD20), daclizumab (anti-CD25), alemtuzumab (anti-CD52) y globulina antitimocítica, que dan lugar a resultados falsos positivos (39)(40)(41)(42)(43).…”

Section: Prueba Cruzada Por Citometría De Flujounclassified

Aspectos técnicos y clínicos de la prueba cruzada de histocompatibilidad en el trasplante de órganos sólidos

et al. 2022

View full text Add to dashboard Cite

La presencia de anticuerpos dirigidos contra los antígenos leucocitarios humanos (Human Leukocyte Antigens, HLA) que se expresan en las células del donante, es uno de los factores de riesgo más importantes asociados con las complicaciones clínicas después del trasplante. La prueba cruzada es una de las pruebas de histocompatibilidad más eficaces para la detección de anticuerpos específicos contra el donante en los receptores de injertos. En los primeros métodos de la prueba cruzada, se utilizaba la citotoxicidad dependiente del complemento, que es útil para detectar dichos anticuerpos responsables del rechazo hiperagudo del injerto, pero carece de la sensibilidad adecuada. Por ello, se desarrollaron métodos de pruebas cruzadas más sensibles, entre ellas, la prueba cruzada por citometría de flujo que hoy se considera el método preferido.En este artículo se revisa la evolución de la prueba cruzada y los factores más importantes que deben tenerse en cuenta al realizarla y al interpretar los resultados de esta prueba fundamental para la supervivencia a largo plazo del injerto.

show abstract

Section: Prueba Cruzada Por Citometría De Flujounclassified

Aspectos técnicos y clínicos de la prueba cruzada de histocompatibilidad en el trasplante de órganos sólidos

et al. 2022

View full text Add to dashboard Cite

show abstract

“…While the number of CD34 + cells in a HCT graft and conditioning regiment are among the most important factors in overall HCT graft quality, 11 understanding HLA expression levels and patterns on hematopoietic stem cells and progenitor cells at the time of transplantation could provide valuable insights into how HLA expression can alter HCT outcome. A better understanding of HLA expression in a cell population could address gaps in knowledge such as rejection risk when crossing HLA antibodies, variability in flow cytometric crossmatch (FCXM) results, 12,13 impact of enzymatic treatment on HLA, 14 and even changes in expression induced by medications 15 . Previous studies have shown that variable levels of HLA‐C and HLA‐DPB1 can affect GVHD 16,17 .…”

Section: Introductionmentioning

confidence: 99%

Specificity of HLA monoclonal antibodies and their use to determine HLA expression on lymphocytes and peripheral blood stem cells

Peton,

Taniguchi,

Mangiola

et al. 2023

HLA

View full text Add to dashboard Cite

HLA Class I and II expression are known to differ locus‐to‐locus, however, HLA expression on the cell‐surface is frequently reported as the total amount of HLA Class I or II antigens. This is despite evidence that indicates the differential expression of HLA can influence patient outcomes post‐transplantation. Although numerous commercially available HLA monoclonal antibodies (mAbs) exist to characterize HLA expression, there is currently a lack of detailed information regarding their reactivities to HLA specificities. The specificities of locus‐specific HLA mAbs (nine Class I and four Class II mAbs) were evaluated by two solid‐phase Luminex single antigen bead assays. The reactivity patterns of these mAbs were then confirmed by flow cytometry using lymphocytes and PBSCs (peripheral blood stem cells). Out of the 13 HLA mAbs tested, only four (one Class I and three Class II mAbs) displayed intra‐locus reactivity without also reacting to inter‐locus specificities. Epitope analysis revealed the presence of shared epitopes across numerous HLA loci, explaining much of the observed inter‐locus reactivity. The specificity of the HLA mAbs seen in solid‐phase assays was confirmed against PBSCs and lymphocytes by flow cytometry. Using this method, we observed differences in the cell surface expression of HLA‐C, HLA‐DR, HLA‐DQ, and HLA‐DP between PBSCs and lymphocytes. Our results emphasize the need to characterize the reactivity patterns of HLA mAbs using solid‐phase assays before their use on cells. Through understanding the reactivity of these HLA mAbs, the cellular expression of HLA can be more accurately assessed in downstream assays.

show abstract

Choosing the Right Patient for Lung Transplantation: Assessment of Histocompatibility and Sensitization Status

Mangiola

Zeevi

2021

Contemporary Lung Transplantation

View full text Add to dashboard Cite

Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch

Cited by 4 publications

References 31 publications

Aspectos técnicos y clínicos de la prueba cruzada de histocompatibilidad en el trasplante de órganos sólidos

Aspectos técnicos y clínicos de la prueba cruzada de histocompatibilidad en el trasplante de órganos sólidos

Specificity of HLA monoclonal antibodies and their use to determine HLA expression on lymphocytes and peripheral blood stem cells

Choosing the Right Patient for Lung Transplantation: Assessment of Histocompatibility and Sensitization Status

Contact Info

Product

Resources

About